PROBIOTIC 40 BILLION CFU
HELPS RESTORE THE NATURAL BALANCE OF BACTERIA IN YOUR GUT (INCLUDING YOUR STOMACH AND INTESTINES) WHEN IT’S BEEN DISRUPTED BY AN ILLNESS OR TREATMENT
Probiotic 40 Billion CFU’s is a powerful blend of 4 scientifically studied Bifidobacterium and Lactobacillus strains and 40 billion colony forming units (CFU’s). Probiotic bacteria are critical for healthy digestion, help maintain the integrity of the
intestinal lining, support proper intestinal motility and participate in the detoxification process.*
Probiotic 40 Billion CFU’s features the most innovative delivery system (stomach acid protection) that ensures strains can survive the stomach acids and reach deep into the small intestine, alive.
This laboratory grade formula is packed in vegetarian capsule that is allergen-free, glucose-free, kosher, and lactose-free
and is designed to pass through your stomach acid and bile and get straight to your gut to populate your gut with good bacteria.
Probiotic 40 Billion CFU’s is designed to provide a high potency and balance of beneficial bacteria. By taking this product on a regular basis Probiotic-40 can help assist in maintaining healthy intestinal flora. This supplement also contains FOS to help with acidophilus and bifidus.
These nutrients help the body in the following ways:
- Support digestive health to help ease gas, bloating, constipation and occasional diarrhea.*
- Promote immune health so you can get and stay healthy.*
- Improve nutrient absorption so you can get more out of the foods you eat.*
- Restore balance of beneficial bacteria in digestive tract for optimal health.*
- Replenish healthy bacteria killed by antibiotics.*
Feel Better and Improve Your Health!
Check out some of our customer reviews…
FREQUENTLY ASKED QUESTIONS (FAQs)
We have compiled a list of the most frequently asked questions here, with answers by our panel of experts.
PROBIOTIC 40 BILLION CFU is a therapeutic, multi-strain probiotic combination that is specially formulated with 40 billion active cells* to fortify the gastrointestinal tract with healthy bacteria.
PROBIOTIC 40 BILLION CFU is a shelf-stable probiotic supplement that contains the patented MAKTREK delivery system to help improve probiotic survivability from stomach acid. With 40 Billion live active cultures and added FOS Prebiotic fiber to improve overall efficacy, PROBIOTIC 40 BILLION CFU helps support a healthy gut and immune system with a Non-GMO and gluten-free formula.
Probiotics as a whole are designed to help with a range of different problems found within the body. The key to really get the benefits of a probiotic supplement is to make sure you are taking a product that has active CFU/g’s by the time it reaches your system.
There are a couple ways to achieve this, one being fridge storage of your probiotics the other and most common is to put enough in there that the desired amount will still be in the capsules once it passes through the stomach. To ensure that Yuuto Nutrition is providing the best quality of supplement. We do this by using the MAK Trek Bypass process by using a natural marine polysaccharides derived from brown seaweed. This process creates a protective layer around the capsule keeping the probiotics usable while it is in the stomach. Once the supplement is released from the stomach to the digestive tract. The capsule is able to break down and release the probiotic in to the body.
The main 4 strains of probiotics used in our private label probiotic 40 billion supplement are as follows:
- Lactobacillus acidophilus – naturally found in the intestinal tract and helps in maintaining the intestinal flora numbers.
- Bifidobacterium Lactis – known for its ability to helps to stimulate the body’s immune response.
- Lactobacillus Plantarum – known for its benefits in helping support the digestive tract.
- Lactobacillus Paracasei – known for helping to boost energy levels
- Prebiotic Fructooligosaccharides (FOS) – known for balance of important bacteria in the digestive tract. Helps you digest food, cleanse your system, and enhance your immunity.
PROBIOTIC 40 BILLION CFU CAPSULES MAY BE A USEFUL DIETARY SUPPLEMENT FOR:
- People who have recently taken a course of antibiotics;
- People who don’t follow healthy, balanced diet rich in fibre-rich fruit, veggies, legumes and whole grains;
- People who have had radiotherapy or chemotherapy;
- People who are frequently treated for yeast infections such as Candida (thrush);
- People with urinary tract infections;
- People who want to support their immune function and nutrient absorption;
- People who have had a bout of diarrhoea (for example, from food poisoning or a viral infection);
- People with acute diarrhoea;
- People suffering from acid reflux;
- People suffering from stomach ulcers;
- Women suffering from vaginal yeast infections.
As a dietary supplement, take two (2) veggie capsules once daily. For best results, take one (1) capsule during the day and one (1) capsule in the evening. Do not exceed two capsules per day. For best results use daily and consistently. You may want to set a reminder on your phone or computer to make sure you take your supplements at correct time.
To minimize stomach acid and keep probiotic microorganisms alive, you should take Probiotic 40 Billion CFU’s supplement on an empty stomach. Taking Probiotic 40 Billion CFU’s about 30 minutes before each meal is a good way maximize the survival of the probiotic microorganisms.
Results may vary from person to person, but in most cases, we would expect the beneficial effects of the nutrients and bioactive elements in PROBIOTIC 40 BILLION CFU capsules to build over several weeks, with noticeable results in one to three months. A regular intake is recommended and should be used in conjunction with a balanced and healthy diet. There is no maximum length of time over which PROBIOTIC 40 BILLION CFU may be used. If you are unsure about taking supplements consult a doctor or pharmacist before use.
- Serving Size2 Vegetarian Capsules
- Servings Per Container30
- Calories from Fat0
- Food ComponentAmount/Serving% Daily Value*
- Yuuto™ Proprietary Blend of Probiotic Bacteria 40 Billion CFU
- MAKTREK (Bi-Pass Technology)
- Lactobacillus Acidophilus (La-14)
- Bifidobacterium Lactis (Bl-04)
- Lactobacillus Plantarum (Lp-115)
- Lactobacillus Paracasei (Lpc-37)
- Marine Polysaccharide Complex
- Prebiotic Fructooligosaccharides (FOS)
Inactive Ingredients: Cellulose (Vegetable Capsule), Rice maltodextrin, L-Leucine.
- 100% All Natural
- Suitable for Vegans: No
- Suitable for Vegetarians: No
- Vegetarian Capsule: Yes
- Third Party Tested: Yes
- 60 Veggie Capsules: 1 Month Supply
- Non-GMO / Dairy Free / Gluten Free / Wheat Free: Yes/Yes/Yes/Yes
- U.S.A manufactured in a GMP facility.
- Yuuto™ Nutrition proudly uses only the highest quality ingredients.
This product is formulated with 40 billion CFU per 2 caps and to deliver a minimum potency of 20 billion CFU per 2 caps through the best by date.
The Supplement Facts labeling information contained within this website should be regarded as the most up to date and may differ from product labeling that you have purchased. Please consult your product package for information, including allergens, specific to the product you have purchased.
This information is not intended to replace orthodox medical treatment, but is offered as additional, complementary information.
Food supplements must not be used as a substitute for a varied, nutritional and balanced diet. If you are pregnant, breastfeeding, taking any medication or are currently undergoing medical advice, please consult a doctor or healthcare professional before use.
Refrain from taking the food supplements if adverse reactions occur and consult a doctor.
Keep out of reach of young children.
Do not use if the goods are received without a tamper strip securely in place.
All Yuuto Nutrition products come with 30-day risk-free money back guarantee. If you do not see results after taking the product for 30 days, you can return your empty bottle for a full product refund. For full details on our guarantee, visit our Shipping and Returns page.
 Sanchez, M., Darimont, C., Drapeau, V., Emady-Azar, S., Lepage, M., Rezzonico, E., . . . Tremblay, A. (2013). Effect of Lactobacillus rhamnosus CGMCC1.3724 supplementation on weight loss and maintenance in obese men and women. British Journal of Nutrition, 111(08), 1507-1519.
 Burton, J., Chilcott, C., Moore, C., Speiser, G., & Tagg, J. (2006). A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol Journal of Applied Microbiology, 100(4), 754-764.
 Groeger, D., O’Mahony, L., Murphy, E. F., Bourke, J. F., Dinan, T. G., Kiely, B., . . . Quigley, E. M. (2013). Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes, 4(4), 325-339.
 Chen, Y., Wei, L., Chiu, Y., Hsu, Y., Tsai, T., Wang, M., & Huang, C. (2016). Lactobacillus plantarum TWK10 Supplementation Improves Exercise Performance and Increases Muscle Mass in Mice. Nutrients, 8(4), 205. doi:10.3390/nu8040205
 Gill HS, Rutherfurd KJ, Cross ML, Gopal PK. Enhancement of immunity in the elderly by dietary supplementation with the probiotic Bifidobacterium Lactis HN019. Am J Clin Nutr. 2001 Dec;74(6):833-9.
 Waller PA, Gopal PK, Leyer GJ, Ouwehand AC, Reifer C, Stewart ME, Miller LE. Dose-response effect of Bifidobacterium Lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scand J Gastroenterol. 2011 Sep;46(9):1057-64.
 Latvala S., et al. (2017). Effect of probiotic Bifidobacterium lactis BL-04 on host responses and microbiota in experimental rhinovirus infection in healthy adults.
 Conference Proceedings of IPC2017. Paper presented at the International Scientific Conference on Probiotics and Prebiotics, Budapest (p. 37.). IPC2017
 Waller PA, Gopal PK, Leyer GJ, et al. Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults. Scandinavian Journal of Gastroenterology. 2011;46(9):1057-1064. doi:10.3109/00365521.2011.584895
 Whorwell PJ. Do Probiotics Improve Symptoms in Patients with Irritable Bowel Syndrome? Therapeutic Advances in Gastroenterology. 2009;2(4 Suppl):37-44. doi:10.1177/1756283X09335637.
 Tabbers MM, Chmielewska A, Roseboom MG, et al. Effect of the consumption of a fermented dairy product containing Bifidobacterium lactis DN-173 010 on constipation in childhood: a multicentre randomised controlled trial (NTRTC: 1571).
 BMC Pediatrics. 2009;9:22. doi:10.1186/1471-2431-9-22.
 Chouraqui et al. Acidified milk formula supplemented with Bifidobacterium lactis: impact on infant diarrhea in residential care settings. J Pediatr Gastroenterol Nutr. 2004 Mar;38(3):288-92
 Depending on the experimental setting, L. paracasei has different effects on cytokines.
 It both elevates and suppresses pro-inflammatory cytokines TNF-α (R,R,R,R,R), decreases (R,R) or increases IL-1β (R,R), and inhibits (R) or elevates IFN-γ (R,R).
 L. paracasei mostly induces IL-12 (R,R,R,R) (in some studies decreases: R,R), and increases the proportion of NK cells (R), while reducing the Th-2 response (R,R).
 L. paracasei mostly increases IL-10 (R,R, R,R) ( a study where IL-10 is decreased: R).
 L. paracasei decreases TGF-β1(R,R), and increases TGF-β2 (R).
 L. paracasei increases IL-8 (R), decreases IL-2, IL-4, IL-5, and IL-13 (R,R, R,R). and both decreases and increases IL-6 (R,R).
 L. paracasei increases IgA (R, R), and decreases IgG4 (R) and IgE (R).
 L. paracasei stimulates iNOS and NO (R).
 L. paracasei increases RANTES, IP-10 (R) and ANGPTL4 (R).
 L. paracasei lowers PPAR-γ (R,R).
 It decreases MIP-1α (R), CCL-20 (R), PTGS2 (R), COX-2, PGE2 (R), TLR-4, NOX-4, MCP-1, PPAR-δ (R), CCAAT/ C/EBPβ, C/EBPα and HR-LPL (R).
 L. paracasei increases CD4+ T cell and B cell proliferation (R) and upregulates the CD4+CD25+Foxp3+Treg cell responses (R).
 It reduces neutrophil infiltration (R) and attenuates eosinophil influx in the lungs (R,R,R).
 L. paracasei increases the expression of almost all TLR signaling genes (R).
 L. acidophilus enhances natural killer cell (NK) activity (R,R).
 L. acidophilus decreases NF-κB (R,R) and increases IL-8 (R).
 In influenza, L. acidophilus increases eotaxin, CSF1, IL-1β, RANTES, and IFN -α in the lung, and increases IL-17 in the intestine (R).
 L. acidophilus can upregulate IL-1α, IL-1β, CCL2, and CCL20, and activate TLR2 in intestinal epithelial cells (R).
 L. acidophilus increased the secretion of IFNγ from T-cells in fatigued athletes (R).
 L. acidophilus suppresses Th2-dominant inflammation by activating regulatory T cellsand Th1 helper T cells (R).
 L. acidophilus increases TGF-β (R,R,R,R).
 L. acidophilus decreases NF-κB activity (R,R).
 L. acidophilus suppresses IL-17 and IL-23 (R), TNF-α, IL-8, MIR21 (R,R), IL-6, and IL-12 (R).
This probiotic can both increase and decrease IL-12 (R,R).
 It stimulates IL-10 (R).
 L. acidophilus induces intestinal IgA (R).
 L. acidophilus inhibits iNOS and PTGS-2 (R).
 L. acidophilus suppresses IgE (R, R), IL-4 (R,R), IL-17A and IL-6 (R,R).
 L. acidophilus increases TGF-β and IgA (R,R,R,R).
 L. acidophilus both increases and decreases IFN-γ (R,R) and IL-10 (R,R).
 L. acidophilus increases CD25 and FOXP3 (R), and decreases RORγt (R).
 L. acidophilus significantly increases CD4(+)CD25(+)Foxp3(+) T cells (R), decreases the proliferation of CD4(+) T cells stimulated with antigen, and kills antigen-stimulated T cells (R).
 L. acidophilus improves peritoneal macrophage functions, stimulates NO and IL-6, and inhibits PGE2 (R).
 L. acidophilus improves lymphocyte functions and stimulates IL-2 (R).
 L. acidophilus increases catalase (CAT) activity (R).
 L. acidophilus reverses age-related decline in PPARα, SMP-30 and klotho (R).
 L. acidophilus alters the cytokine production in tumor into a Th1 protective pattern, favorable to anti-tumor immunity (R,R).
 L. acidophilus inhibits the expressions of genes involved in tumor angiogenesis and survival VEGF and HIF-1α (R).
 It upregulates TIMP-3, HIF-2α, HO-1 and PAI-1 (R).
 It increases IFN-γ and decreases IL-4 (R).
 Rondanelli M, et al. World J Clin Cases. 2015 Feb 16;3(2):156-62. doi: 10.12998/wjcc.v3.i2.156. Review.
 Lin CS, et al. Biomed J. 2014 Sep-Oct;37(5):259-68. doi: 10.4103/2319-4170.138314.
 Gibson GR, Fuller R. J Nutr. 2000 Feb;130(2S Suppl):391S-395S. Review.
 Chiang, BL et al. Eur J Clin Nutr. 2000 Nov; 54(11):849-55.
 Arunachalam, K, et al. Eur J Clin Nutr. 2000 Mar;54(3):263-7.
 Gill, HS et al. J Clin Immunology. 2001 Jul;21(4):264-71.
 Ahmed, M et al. J Nutr Health Aging. 2007 Jan-Feb;11(1):26-31.
 Gopal, Pramod K et al. Nutr Research. 2003 Oct: 1313-28.
 Waller, Phillip et al. Scand J Gastro, 2011; 46: 1057-64.
 Prescott, S.L. et al. Clinical and Expir.Allergy, 2008. 1-9
 Collins MD, Gibson GR. Am J Clin Nutr 1999;69:1052S-1057S.
 Robert J Boyle, Roy M Robins-Browne and Mimi LK Tang. American Journal of Clinical Nutrition, Vol. 83, No. 6, 1256-
1264, June 2006
 Verna EC, Lucak S. Therapeutic Advances in Gastroenterology 2010 3: 307-319
 Rhode CL. Nutr Clin Pract 2009 24: 33-40
 Martin FP et al. “Probiotic modulation of symbiotic gut microbial–host metabolic interactions in a humanized microbiome mouse model.” Molecular Systems Biology. 2008;4(1):157.
 Ussar S, Fujisaka S, Kahn C. “Interactions between host genetics and gut microbiome in diabetes and metabolic syndrome.” Mol Metab. 2016;5(9):795-803.
 Ridaura V et al. “Gut microbiota from twins discordant for obesity modulate metabolism in mice.” Science. 2013;341(6150):1241214.
 Wang Z et al. “Non-lethal Inhibition of Gut Microbial Trimethylamine Production for the Treatment of Atherosclerosis.” Cell. 2015;163(7):1585-1595.
 Kwan Chan Y et al. “Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE−/− mice.” AMB Express. 2016;6:61.
 Hasegawa H et al. “Effects of telmisartan and losartan on cardiovascular protection in Japanese hypertensive patients.” Hypertension Research. 2011;34:1179–84.
 Khalesi S et al. “Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials.” Hypertension. 2014 Oct;64(4):897-903.
 Hsiao E et al. “The microbiota modulates gut physiology and behavioral abnormalities associated with autism.” Cell. 2013;155(7):1451-1463.
 Denou E et al. “The Intestinal Microbiota Determines Mouse Behavior and Brain BDNF Levels.” Gastroenterology. 2011;140(5):S-57.
 Desbonnet L et al. “Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression.” Neuroscience. 2010 Nov 10;170(4):1179-88.
 McKean J et al. “Probiotics and Subclinical Psychological Symptoms in Healthy Participants: A Systematic Review and Meta-Analysis.” J Altern Complement Med. 2017 Apr;23(4):249-258.
 Turnbaugh P et al. “An obesity-associated gut microbiome with increased capacity for energy harvest.” Nature. 2006;444:1027-1031.